Multispectral Optoacoustic Tomography in Patients With Cystic Fibrosis
NCT ID: NCT06063785
Last Updated: 2023-10-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30 participants
OBSERVATIONAL
2023-10-01
2025-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study, the degree of liver fibrosis will now be investigated in adult patients with cystic fibrosis using Multispectral Optoacoustic Imaging (MSOT). In addition, gastrointestinal passage will be studied non-invasively to investigate another affection of the gastrointestinal system.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Detection of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity in Rectal Tissues From Human Subjects
NCT01078740
Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects
NCT02603666
The Use of Novel Diagnostic Tools to Increase Detection of Early Fibrosis in Cystic Fibrosis Related Liver Disease to Improve Clinical Management
NCT04277819
Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung
NCT01805713
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
NCT03566550
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
By means of new imaging methods, such as multispectral optoacoustic tomography, it is possible to examine not only the body's own substances but also substances foreign to the body. With Multispectral Optoacoustic Imaging (MSOT), similar to conventional sonography, a transducer is placed on the skin and instead of sound, energy is applied to the tissue by means of light flashes. This leads to a constant alternation of minimal expansions and contractions (thermoelastic expansion) of individual tissue components or molecules. Previous studies have shown that quantitative determination of hemoglobin can provide information on blood flow and inflammatory activity in the intestines of adult patients with Crohn's disease. Also, fibrotic changes in the liver can probably be detected with this method, similar to that in muscle tissue. Furthermore, we have recently shown that orally ingested Indocyanine green (ICG) can be detected in the small intestine and thus conclusions can be drawn about gastrointestinal passage, without the use of ionizing radiation. In this study, the degree of liver fibrosis will now be investigated in adult patients with cystic fibrosis using MSOT. In addition, gastrointestinal passage will be studied non-invasively to investigate another affection of the gastrointestinal system.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CF with liver affection
CF patients with proven CF hepatopathy
Acoustic Radiation Forced Impulse Imaging
Measurement of Liver stiffness
Multispectral Optoacoustic Tomography
Measurement of optoacoustic spectra in liver and gastrointestinal tract
CF without liver affection
CF patients without proven CF hepatopathy
Acoustic Radiation Forced Impulse Imaging
Measurement of Liver stiffness
Multispectral Optoacoustic Tomography
Measurement of optoacoustic spectra in liver and gastrointestinal tract
Healthy volunteers
Healthy volunteers without liver affection
Acoustic Radiation Forced Impulse Imaging
Measurement of Liver stiffness
Multispectral Optoacoustic Tomography
Measurement of optoacoustic spectra in liver and gastrointestinal tract
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acoustic Radiation Forced Impulse Imaging
Measurement of Liver stiffness
Multispectral Optoacoustic Tomography
Measurement of optoacoustic spectra in liver and gastrointestinal tract
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Molecular genetic confirmed diagnosis of cystic fibrosis.
* Age over 18 years
* Written informed consent
Patient cohort "Cystic Fibrosis with CF-related liver disease":
* Molecular genetic confirmed diagnosis of cystic fibrosis
* Presence of CF-related liver disease based on Colombo criteria:
* Hepato- and/or splenomegaly
* Persistent elevation of transaminases in the serum
* Sonographic evidence of liver involvement
* Age over 18 years
* Written informed consent
"Volunteer Subjects":
* Age over 18 years
* Written informed consent
Exclusion Criteria
* Pregnancy
* Breastfeeding mothers
* Tattoo in the area of the examination
* Subcutaneous fat tissue over 3 cm
Patient cohort "Cystic fibrosis without CF-related liver disease":
* Taking systemic glucocorticoids or immunosuppressants as part of a permanent medication regimen.
* Presence of CF-related liver disease based on Colombo criteria:
* Hepato- and/or splenomegaly.
* Persistent elevation of transaminases in the serum
* Sonographic evidence of liver involvement.
* Acute exacerbation of infection
Patient cohort "Cystic fibrosis with CF-related liver disease":
* Taking systemic glucocorticoids or immunosuppressants as part of a permanent medication regimen.
* Decompensation of CF-related liver disease
* Acute exacerbation of infection
"volunteer subjects":
* Presence of liver disease
* Use of systemic glucocorticoids or immunosuppressants in the context of permanent medication
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Adrian Regensburger
UNKNOWN
University of Erlangen-Nürnberg Medical School
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alexander Schnell
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexander Schnell
Role: PRINCIPAL_INVESTIGATOR
Department of Pediatric and Adolescent Medicine, University Hospital Erlangen
Adrian P Regensburger
Role: PRINCIPAL_INVESTIGATOR
Department of Pediatric and Adolescent Medicine, University Hospital Erlangen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Erlange, Department of Pediatrics
Erlangen, Bavaria, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CF_MSOT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.